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Abstract
The long-term graft survival in renal transplantation results is still controversial, the tox-
icity and adverse reactions of the immunosuppressive drugs are implicated, as well as 
cellular and humoral antigen-specific immune mechanisms; therefore, different strategies 
for adapting immunosuppression are used to reduce the complications associated with 
the use of these drugs. Calcineurin inhibitors (CNI) require an adequate dose-dependent 
concentration leading to the appearance of drug-related adverse reactions. The variability 
in the required dose of CNI leads to minimization strategies that do not result in a higher 
acute rejection (AR) incidence when compared to other immunosuppressive agents. Early 
steroid withdrawal is another strategy, although with an increase in AR, but without an 
impact on the function and survival of the renal graft. The reduction of mycophenolate 
mofetil to 1.5 g/day seems to be a therapeutic option, decreasing the infectious, hematolog-
ical and gastrointestinal adverse reactions. Finally, alemtuzumab, bortezomib, belatacept 
and cellular therapies are in the search for the new treatments, whose premise is the induc-
tion of donor-specific nonresponse in the context of operational tolerance or mixed chime-
rism. The use of adapted and adequate immunosuppression has led to variable results and 
some are very encouraging; however, they must be validated with experimental studies.
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1. Introduction
Renal transplantation (RT) is currently considered the best therapeutic option for renal replace-
ment therapy in patients with end-stage renal disease (ESRD), with controversial results related 
to long-term graft survival [1–3]. Several factors can contribute to loss of the renal graft over time, 
which may be nonimmunological in nature, such as chronic nephrotoxicity due to drugs used 
for transplantation maintenance [particularly calcineurin inhibitors (CNI) tacrolimus (TAC) and 
cyclosporin] or for the side effects of immunosuppression when corticosteroids are involved, 
such as: infections, neoplasms, dyslipidemia, hypertension, cardiovascular disease, and new-
onset diabetes mellitus (NODAT) that can lead to high mortality in patients with a functional 
graft [4–6]. Other conditions that induce long-term graft loss are the antigen-specific humoral 
and cellular immune mechanisms that contribute to an increase in the number and severity of 
episodes of acute rejection (AR), inducing chronic alloimmune damage [5–14]. These damage 
mechanisms raise the awareness that there must be a balance in posttransplantation immuno-
suppression; however, the new and powerful immunosuppressive drugs used today, and the 
alarming loss of kidney grafts, particularly due to the side effects of immunosuppression, have 
motivated transplant centers globally to try to minimize, suspend, or change the immunosuppres-
sive maintenance drugs to try and further reduce the complications associated to them [15–39].
2. Minimizing immunosuppression with calcineurin inhibitors in 
kidney transplantation
The introduction of CNI has achieved exceptional short-term results in recent years in the field 
of allograft transplants, especially by reducing the rate of AR episodes, reaching, in the last 
20 years, an overall graft survival of more than 90% in the first year [39]. However, the attention 
now focuses on the search for better long-term outcomes with strategies that sustain a low AR 
rate along with a decrease in the side effects of immunosuppression. The immunosuppressants 
have three effects: the therapeutic effect (rejection of suppression), unwanted consequences 
related to immunosuppression (infections, neoplasms, metabolic and hemodynamic disorders), 
and the nonimmune toxicity to tissues [40]. The nonimmune toxicity is immunosuppressive 
agent-specific and is related to the mechanism of action of the drug, since they target-specific 
molecules with certain functions in nonimmune tissues, conditioning progressive tissue dam-
age, and gradual kidney graft failure. This, coupled with the death of the patient with a func-
tional graft, encourages the new concept of focusing on nonimmune factors that intervene in 
the long term, evoking enthusiasm for strategies to minimize the side effects of CNIs.
3. Pharmacodynamics and nonimmune toxicity of the calcineurin 
inhibitors
In the classification of immunosuppressants, small molecules are included (from which the 
immunophilin-binding drugs are derived, such as CNIs, mechanism target of rapamycin 
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(mTOR) inhibitor (imTOR), nucleotide blocking agents, and antimetabolites); the protein-
depleting and nonlymphocyte-depleting agents (monoclonal and polyclonal antibodies), the 
intravenous immunoglobulin, and corticosteroids [40]. The effects of CNI are proportional to 
the serum concentration levels, since this depends on the saturation dose of its targets [40], 
which makes the dosage and the control of serum levels important in maintaining the balance 
between the desired immunosuppressant effect and the unwanted toxicity.
Cyclosporin A (CsA) is a fungal origin polypeptide (derived from Tolypocladium inflatum), 
composed of 11 amino acids, with a molecular weight of 1203 Da, which interacts by binding 
to its cytoplasmic receptor (cyclophilin); a protein from the family of immunophilins, forming 
a complex that binds to the calcineurin, inhibiting its normal phosphatase action on regula-
tory nuclear proteins (nuclear factor -KB and activator protein 1), preventing the cytokine 
production (IL-2), and eventually the T lymphocyte activation [41]. The adverse reactions to 
CsA, related to the serum concentration of the drug, include: nephrotoxicity, hypertension, 
hyperlipidemia, gingival hyperplasia, hirsutism, and tremor [42]; and, less frequently, hemo-
lytic uremic syndrome, and NODAT [40].
In 2004, a longitudinal cohort where 888 renal biopsies were collected from 99 patients who 
were in immunosuppressive treatment with CsA for 10 years after renal transplantation, was 
evaluated; finding arteriolar hyalinosis as the most sensitive marker for nephrotoxicity due 
to CsA [43]. Another CNI introduced in the mid-1990s, that was initially called FK506 and is 
currently known as TAC, is a macrolide isolated from the fungi Streptomyces tsukubaensis that 
possesses suppressive effects similar to CsA (cell-mediated and humoral immune responses) 
[41]. The TAC binds to a protein called FKBP12 (binding protein of FK506–12) and a complex 
that inhibits the phosphatase activity of calcineurin, preventing the activation of the T cell, 
and selectively affecting the transcription of IL-2 and other cytokines. The adverse reactions 
are similar to those of CsA but with less incidence of hypertension, hyperlipidemia, hirsutism, 
and gingival hyperplasia; however, the incidence of NODAT and nephrotoxicity is higher [44].
The mechanism through which nephrotoxicity occurs is explained by the endothelial dys-
function associated with reduced production of local vasodilators (nitric oxide and prosta-
glandins) and increased production of vasoconstrictors (endothelin and thromboxane) [45].
The determination of the serum levels of the CNI is part of the management of immunosup-
pression in transplant recipients, due to the variability between patients (and the intra-patient 
variability). The inter-individual variability with TAC is explained by polymorphisms in 
genes that encode transporter proteins and enzymes that metabolize the drug. The TAC is 
metabolized in the intestine, liver, and kidney by cytochrome P450 (CYP) 3A4 and 3A5. Inter-
individual differences in CYP3A activity are the most important determinants of variability in 
TAC metabolism. Polymorphisms in the CYP3A5 gene explain 40–50% of the variability in the 
TAC dose requirement to maintain adequate serum levels: the most studied one is the single 
nucleotide polymorphism CYP3A5*3. This allele causes a reduced enzymatic activity associat-
ing with the need to reduce the administered dose of TAC. On the other hand, when CYP3A5 
is expressed, a dose of about 50% higher is required [46, 47]. To a lesser extent, the CYP3A4 
genotype with impact on the determination of doses in transplant patients receiving TAC has 
also been identified. Individuals carrying the CYP3A4 * 1B allele reported up to a 35% dose 
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reduction in order to achieve a therapeutic concentration. Similarly, it has been identified that 
the CYP3A4 * 22 variant reduces the enzymatic activity of CYP3A4, associated with a lower 
dose requirement. On the other hand, there are ethnic considerations that participate in allelic 
variability since Caucasian patients are commonly carriers of the CYP3A5 * 3 allele [46].
4. Minimization strategies of immunosuppression with calcineurin 
inhibitors
Given the nonimmunological toxic effects of CNI, two general strategies to reduce CNI are 
proposed: de novo minimization, where maintenance immunosuppression with CNI is sought 
immediately after transplantation at low doses subsequent to a powerful induction; and the sec-
ond strategy, selective minimization, in which a class of immunosuppressants is avoided, show-
ing a reduction of the undesired effects related to the drug. The Symphony study evaluated 1645 
patients divided into four groups: (1) Standard dose of CsA, mycophenolate mofetil (MMF), and 
prednisone (PDN); (2) Low dose of CsA with induction therapy with daclizumab; (3) Low dose 
of TAC with induction with daclizumab; (4) Low dose of sirolimus (SRL) with induction with 
daclizumab. The primary aim was to reduce the nephrotoxicity using a low dose of CNI and SRL 
and to secondarily reduce the side effects, at the same time as maintaining the efficacy in terms of 
avoiding acute rejection, improving the overall survival of the patient and the graft. Their results 
at 1 and 3 years showed a better glomerular filtration rate (GFR) and graft survival in the group 
with low dose of TAC, as well as a low AR rate, compared with the SRL group [42, 48].
On the other hand, avoiding CNIs is the complete omission of these drugs from the mainte-
nance immunosuppression regimen, while minimization schemes use reduced doses of CNI 
in order to avoid their nephrotoxicity [49]. Larso et al., compared regimens without CNI (SRL, 
MMF and PDN) and with CNI (TAC, MMF and PDN), in RT recipients, with similar results 
at 12 months in patient survival (98% SRL, 96% TAC, p = 0.42) and graft survival (94% SRL, 
92% TAC, p = 0.95), as well as in the incidence of AR between both groups [50]. The regimens 
without CNI were also evaluated in the ORION51 study, which compared the efficacy of 
three schemes; (1) SRL + TAC with discontinuation of CNI at 13 weeks; (2) SRL + MMF; and 
(3) TAC + MMF. The SRL + MMF group presented more AR events (32.8%) compared to 
SRL + TAC (17.4%) and TAC + MMF (12.3%); however, the graft and patient survival were 
similar and there was the presence of hyperlipidemia in the group treated with SRL and 
NODAT in the group with TAC (Table 1) [51].
The BENEFIT study [52] compared two regimens (an intensive and a less intensive dose) with 
betalacept (selective T cell co-stimulation blocker) versus CsA in patients with living donor RT 
with standard criteria; finding better renal function with belatacept regimens (GFR of 65, 63, 
and 50 ml/min, respectively) but with a lower AR rate with CsA (22, 17 and 7%, respectively).
On the other hand, Weir et al. [53], who evaluated the efficacy and safety of the combination 
of MMF and SRL versus MMF and a CNI (TAC or CsA) at 24 months, found that the GFR was 
higher in the MMF/SRL regimen, with a similar AR rate in both groups.
Finally, a meta-analysis and systematic reviews related to these strategies have recently 
been published, with the aim of preventing nephrotoxicity and graft loss by a nonimmune 
character.
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Immunosuppressor Used dose in renal 
transplant
Adverse reactions Minimization strategy
Tacrolimus 0.1–0.15 mg/kg/day 
divided in two doses
Nephrotoxicity, tremor, 
headache, dizziness, gingival 
hyperplasia, hypertension, 
carbohydrate intolerance, 
increased risk of infections and 
neoplasms.
Dose reduction; with lower 
nephrotoxicity without a higher 
acute rejection rate.
Cyclosporine 5–8 mg/kg/day 
divided in two doses
Nephrotoxicity, hypertension, 
hyperlipidemia, gingival 
hyperplasia, hirsutism, 
lymphoproliferative disorders 
associated to EBV, Kaposi 
sarcoma, TMA, HUS.
Dose reduction; improves the 
glomerular filtration rate and 
graft survival when compared to 
mTOR inhibitor.
Mycophenolate mofetil 2 g/day orally divided 
in two doses
Gastrointestinal: abdominal 
pain, nausea, vomits, diarrhea.
Hematological: anemia, 
leukopenia, thrombocytopenia, 
increased risk of infections 
(especially viral), neoplasms.
Dose reduction not less than 
1.5 g/day can decrease the 
gastrointestinal, hematological 
and infectious adverse reactions 
without an acute rejection rate 
increase.
Prednisone 0.5–1 mg/kg, orally 
divided in two 
doses with a taper 
of 5–10 mg/day 
indefinitely
Susceptibility to infections, 
obesity, osteonecrosis 
(avascular necrosis), 
hyperglycemia, hypertension, 
dyslipidemia, peptic ulcer, 
cushinoid features, long-term 
myopathy, osteoporosis, 
atherosclerosis, skin atrophy, 
cataracts.
Steroid withdrawal; better graft 
survival, lower risk of mortality, 
decrease in graft dysfunction 
with an improved metabolic and 
hemodynamic profile, although 
with contradictory results 
that may involve higher acute 
rejection rates proved by biopsy 
without affecting the long-term 
graft survival.
Alemtuzumab 30 mg/kg 
intravenously unique 
pre-transplant 
induction dose
Predisposition to severe 
infections (bacterial, viral, 
fungal) and increased risk of 
neoplasms.
Used as pre-transplant induction 
therapy allowing early steroid 
taper, CNI decrease or change 
to mTOR with a reduction 
in AR episodes in the first 
posttransplant year, without 
differences in graft survival in 
patients with low immunological 
risk and conventional therapy.
Bortezomib 1.3 mg/ m 2 
intravenously on day 
1, 4, 8 and 11 for two 
cycles
Peripheral sensory 
neuropathies.
Hematologic: anemia, 
leukopenia, thrombocytopenia
Nausea, diarrhea, weakness.
Used as desensitization 
therapy, severe humoral 
rejection treatment, allowing an 
immunosuppression restart at an 
adjusted dose, being considered 
an immunosuppression 
minimization strategy.
Belatacept 10 mg/kg 
intravenously on 
posttransplant days 1, 
5, 14 and then every 
4 weeks indefinitely
Greater predisposition to 
lymphoproliferative disorders 
not associated to EBV, herpes 
virus and tuberculosis 
infections.
Adjuvant treatment with MMF 
and prednisone maintains a CNI-
free immunosuppression with an 
increase in acute rejection in the 
first 6 months (posttransplant) 
but better long-term renal graft 
function compared with CsA.
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Sawinski et al. [54], evaluated 88 clinical trials regarding CNI reduction strategies associated 
with MMF or imTOR in a meta-analysis (minimization of the CNI without suspending it, 
conversion to another immunosuppressant “imTOR,” and withdrawal of the CNI in the post-
transplant period or never used in the RT); finding the best results with the strategies in which 
the CNI was minimized, especially in the first 6 months without stopping it, with a lower 
incidence of AR (RR 0.80, 95% CI 0.68–0.95), graft loss (RR 0.71 95% CI 0.56–0.9), and better 
graft function and no differences in mortality (RR 0.87, 95% CI 0.66–1.15), compared to stan-
dard regimens with CNI. Nevertheless, it is important to mention that the majority of studies 
were based on CsA induction with basiliximab, thus more research is needed to determine 
the role with other immunosuppressants (TAC and thymoglobulin) and their doses, with the 
aforementioned strategies. Finally, a systematic review of 83 studies that included a total of 
16,156 patients with a removing sample (RR 2.54; CI 95%: 1.56–4.12) or an avoiding sample 
(RR 2.16; CI 95%: 0.85–5.49) of CNI from the immunosuppression maintenance regimen, was 
associated to AR without a difference in graft loss (RR 0.96; CI 95%: 0.79–1.16), and with a 
lower incidence of hypertension in the CNI-abstained groups (RR 0.82, CI 95%: 0.71–0.95) [55].
5. Strategies for removing steroids from immunosuppression in 
kidney transplantation
Another tempting strategy for reduction of posttransplant immunosuppression is to with-
draw or avoid the use of corticosteroids because of the numerous side effects, with the pur-
pose of improving quality of life and reducing cardiovascular mortality.
This intervention has increased from 5 to 35% since the year 2000 until today, in RT recipients 
in the USA. Historically, the removal of steroids has been associated with the risk of precipi-
tating AR [56, 57]; however, long-term safety in terms of patient and graft survival has been 
satisfactory with early steroid withdrawal (ESW); as Rizzaari shows [58] in a 10 year follow-
up of 1241 RT recipients with graft survival, showing similar death in living donor RT recipi-
ents with maintained with steroids (79 vs. 73%) and with even an better survival in deceased 
donor RT (80 vs. 67%) with a report in their survival analyses free of AR, similar between the 
Immunosuppressor Used dose in renal 
transplant
Adverse reactions Minimization strategy
Belimumab Initial dose:120 mg 
intravenously, then 
400 mg IV every 
2 weeks indefinitely
Infusion related (bradycardia, 
myalgias, rash, urticarial, 
hypotension), depression, 
insomnia, nausea, diarrhea, 
bronchitis, pharyngitis, 
increased risk of viral 
infections.
Is in experimental phase, it can 
induce immunologic tolerance 
or mixed chimerism as an 
immunosuppression reduction 
strategy.
TMA, thrombotic microangiopathy; EBV, Epstein-Barr Virus; HUS, hemolytic uremic syndrome; mTOR, mechanistic 
target of rapamycin; CNI, calcineurin inhibitors; CsA, cyclosporine [50, 51, 53, 60, 61, 95, 97, 100, 101, 103].
Table 1. Immunosuppression in renal transplant, adverse reactions and minimization strategies.
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groups with and without corticosteroids. Lopez Soler et al. [59], similarly reported in a cohort 
undergoing ESW with a 10-year follow-up that showed better graft survival (p = 0.023), lower 
risk of mortality (0.23, p ≤ 0.011), and less graft failure (0.57, p = 0.026).
Similar to minimization of the CNI, numerous meta-analyses have been published regarding 
a population undergoing ESW, both in the adult and pediatric populations, concluding, in 
some, a higher rate of AR, especially of mild characteristics, without greater impact in the 
function or graft survival, and with satisfactory results in the metabolic and hemodynamic 
profile, reducing cardiovascular morbidity and mortality (Table 1) [19, 20, 60, 61].
Knight et al. [19], evaluated a meta-analysis of 34 clinical trials with 5637 patients in regimens 
that included withdrawal or nonuse of steroids at any time of the transplantation, and found 
that the withdrawal of steroids was associated with a higher incidence of AR (RR 1.56; 95% CI 
1.31–1.87), but with a lower incidence of hypertension (RR 0.64; 95% CI 0.50–0.83), diabetes 
(RR 0.90; 95% CI 0.85–0.94), and hypercholesterolemia (RR0.96; 95% CI 0.67–0.87); concluding 
that AR had no impact on function or survival of the grafts because it was considered mild.
Zhang et al. [60], in a meta-analysis of 13 clinical trials in 3520 patients with ESW after trans-
plantation found a higher incidence of AR; but when the trials that used TAC were exclu-
sively analyzed, the statistical significance was lost and only remained in those that used 
CsA. Studies that involve corticosteroid withdrawal associated with TAC in the immunosup-
pression regimen, document the development of borderline changes in AR, especially in the 
early stage of transplantation, without impact on function or survival of the graft [23, 62].
The current use of immunosuppression induction with anti-DC25 antibodies (basiliximab) or 
lymphocyte depletion (thymoglobulin) combined with MMF and TAC has favored that the 
minimization or elimination of the use of posttransplant steroids be safe with cell type AR 
rates comparable to those that maintain the use of the posttransplant steroid [16, 17, 20–27, 
29–31, 58, 60, 63–67].
The good results from minimization or suspension of some immunosuppressants are encour-
aging because one of the main associated causes with poor long-term kidney graft survival is 
directly or indirectly related to the side effects of immunosuppressants that cause long-term 
complications and even a higher cardiovascular mortality [4, 11, 43, 68–71].
Experience with this intervention in our transplant center has shown satisfactory short-term 
(12 months) results with similar AR rates in immunosuppression with and without steroids, 
with lower glucose levels, lipids, and better blood pressure parameters, which leads to less 
use of antihypertensive and lipid-lowering drugs in the group without steroids [17, 23]. 
Nonetheless, despite the acceptable results found with these strategies the community dedi-
cated to transplantation is concerned about what happens with these long-term immuno-
suppression strategies, especially since presently one of the main causes of graft loss is the 
chronic antibody-mediated rejection mainly associated to sub-immunosuppression.
Nonetheless, the sub-immunosuppression generated by minimization strategies or suspen-
sion of an immunosuppressant in the posttransplant context causes uncertainty regarding 
the formation of antihuman leukocyte antigen (HLA) antibodies [donor-specific antibodies 
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(DSA) or nondonor-specific antibodies (NDSA)] over time, with an increased risk of anti-
body-mediated AR and graft loss. Some studies show results in the incidence of DSA with 
immunosuppression regimens considered less potent, which could cause the appearance of 
humoral AR and long-term graft loss [33–37]. Kreijveld et al. [72] showed that the reduction 
or removal of TAC from immunosuppression in the posttransplant period does not generate 
antibodies and does not even predict the development of AR. As for steroids, the mechanism 
of suppression of antibodies by the B lymphocyte with the use of these drugs has created the 
idea that avoiding or removing steroids in the posttransplant period favors the appearance 
of antibodies against the major histocompatibility complex (MHC) and against other renal 
donor antigens. Even so, information related to the formation of DSA with the minimization 
or suspension of steroids posttransplantation is scarce [73–75].
6. Antihuman leukocyte antigen antibodies in kidney recipients 
with steroid withdrawal
One of the leading causes of long-term graft loss is interstitial fibrosis and tubular atrophy 
(IFTA) and the appearance of DSA posttransplant, which seems to play an important role in 
graft dysfunction.
The B lymphocyte antibody suppression combined with the use of steroids has created the idea 
that avoiding or removing these drugs in the posttransplant period may induce the appearance 
of antibodies. Unfortunately, there is not sufficient evidence to uphold that the withdrawal of 
steroids contributes to the increase in production of antibodies or if it is associated to a higher 
rejection rate and chronic graft dysfunction, that being with steroids in the immunosuppres-
sion regimen. Delgado et al. [73], in a retrospective study of 43 kidney recipients during post-
transplant antibody monitoring, showed that patients with steroid withdrawal did not develop 
DSA compared to the steroid maintained group posttransplantation. Drugs such as MMF and 
thymoglobulin, in addition to interacting with T lymphocytes, inhibit the formation of B lym-
phocyte antibodies, so it is possible that the immunosuppression regimens that use these drugs 
provide greater safety even when steroids are avoided or suspended after the transplantation. 
Furthermore, the avoidance or withdrawal of steroids may enhance the myelosuppressive 
effect of MMF, since steroids induce greater activity of the hepatic enzyme uridine diphosphate-
glucoronosyltransferase that degrades MMF [76]. In addition, steroids induce the cytochrome 
P450 isoenzyme 34ª responsible for the metabolism of TAC, and so avoiding these drugs would 
favor the increase of TAC serum levels, thereby increasing their immunosuppressive effect [77]. 
These possible mechanisms suggest that the appearance of DSA induced by the suspension of 
steroids after transplantation could be no different than in the immunosuppression schemes 
maintained by these drugs.
In a clinical trial recently performed at our center with living donor kidney transplant recipi-
ents who underwent protocolized biopsies every 3 months, it was found that the presence of 
AR was no different between patients who had an early steroid removal compared to those 
in which the drugs were sustained. However, the suspension of steroids has generated uncer-
tainty about the risk of developing DSA posttransplant, over the course of time. Due to this 
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concern, our team recently conducted a prospective cohort of 77 patients with low immu-
nological risk (data not yet published) where findings revealed that the presence of cellular 
AR was a predictor for the formation of DSA against class II antigens, coinciding with the 
results of other authors [78]. There is currently little scientific evidence in which the absence 
of steroids in the posttransplant period may generate a greater presence of posttransplant 
DSA. Delgado et al. [73], observed that in a retrospective study of 43 kidney recipients dur-
ing posttransplant antibody monitoring, patients with steroid suspension did not develop 
DSA compared to the group with maintained steroids. On the other hand, de Kort et al. [79] 
recently showed that in a population with steroids suspended using lymphocyte-depleting 
immunosuppressive induction (alentuzumab) and monotherapy with TAC, there was an 
increased risk for the development of DSA from an early posttransplant stage. Our study 
(data not yet published) also showed a higher incidence of DSA in patients with immunosup-
pression therapy without steroids appearing from a very early stage of the transplantation 
(<12 months). Unlike the study by de Kort et al. [79], 97% of our population undergoing 
steroid withdrawal used nonlymphocyte-depleting antibodies (basiliximab) with a double 
immunosuppression maintenance regimen based on MMF and TAC.
The immunoglobulin subclasses (IgG1/IgG3) capable of binding and activating the classical 
complement pathway (C1q) can predict the presence of antibody-mediated AR even with 
phenotypes of more severe damage (extensive microvascular inflammation and increased 
C4d deposition) and risk of kidney graft loss [80–83]. Undoubtedly, the measurement of 
antibody subclasses in patients subjected to a sub-immunosuppression state with minimiza-
tion schemes or suspension of immunosuppression should be considered in order to discern 
whether the presence of these antibodies, according to the ability to fix complement, can 
generate chronic damage and lower the survival of the grafts. Finally, the benefits obtained 
from the nonsteroid schemes in the posttransplant stages in the lipid, metabolic, and blood 
pressure profiles, in our previously reported experience, should be considered for its possible 
risk of activating the immune system [17, 23].
7. Minimization strategies of mycophenolate mofetil in renal 
transplantation
Mycophenolate mofetil (MMF) has been established as the leading immunosuppressive regi-
men in most clinical trials and in almost 100% of the renal transplant centers in the world. 
With the initial use of CsA a daily dose of MMF was established at 2000 mg, while now, since 
the immunosuppressant regimen has changed to TAC significantly improving graft survival, 
the dose of MMF has not been established [84].
The MMF is an antiproliferative drug that requires de-esterification in gastrointestinal tissue 
for its absorption, thus releasing mycophenolic acid (MPA) that is freely absorbed and needs 
a pH > 5.5 to facilitate absorption in the small intestine. The most common use of MMF is still 
the prevention of AR in renal, pulmonary, cardiac, and hepatic organs, in adjunct with other 
immunosuppressive agents, which has shown to reduce AR by 20–40% in RT compared with 
azathioprine (AZA).
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CsA and TAC have a different influence on enterohepatic circulation and the metabolism of 
MPA. The TAC increases serum levels of MMF and therefore exposure of the metabolite in the 
blood circulation in patients undergoing this immunosuppression regimen when compared 
to CsA, while the decrease in MMF dosage combined with TAC has not yet been well studied 
and no conclusive results have been established [85].
Clinical trials have tried to establish the MMF dosage. Doria et al. [86], included 901 patients 
with de novo RT, assigning three study groups with a MMF dose of <2000, =2000, and >2000 mg 
with thymoglobulin and an alemtuzumab-based induction, and no significant differences 
were found at 1 year follow-up regarding AR and graft loss; but they did find an increase, 
though not significant, in hematological complications related to leukopenia, anemia, and 
greater gastrointestinal disorders in patients with MMF doses of 2000 and >2000 mg.
These side effects have also motivated the establishment of adjusted dosing for certain popu-
lations. There are several controversies about whether reducing MMF dose modifies graft 
survival. Ji et al. [87], evaluated 128 patients with a low immunological risk at 12 months 
of follow-up, using immunological induction with basiliximab, methylprednisolone bolus 
(MPD) and TAC with a dosage of 0.1 mg/kg/day divided into two doses, PDN at 1 mg/kg/day 
at dose reduction, and MMF in different doses: = 500, <1500, and >1500 mg; finding, in the low 
dosage groups (=500 and <1500 mg), an increased number of cases of AR, renal graft dysfunc-
tion, and C4d deposition in follow-up biopsies, while the conventional dose group of MMF ≥ 
1500 mg did not present any representative difference. Therefore, it is suggested that the dose 
should be individualized to the demographic characteristics of each population, under an 
integral evaluation of weight and height, and likewise that immunosuppression should not 
be reduced to doses less than 1 g of MMF per day nor suspension of the antimetabolite, since 
it jeopardizes the survival of the graft.
The side effects of MMF are divided into those due to gastrointestinal disease where diarrhea 
is the main manifestation with a frequency of up to 40–50% and in severe cases has been attrib-
uted as a cause of histologically inflammatory colitis type lesions similar to Crohn’s disease.
Within the hematological side effects attributed to the drug there is leukopenia with or without 
neutropenia that can be potentiated by the use of other, concomitant drugs (Valganciclovir, 
trimethoprim with sulfamethoxazole, etc.) during the early period of RT. Other attributable 
side effects are hypogammaglobulinemia and severe anemia, especially in the first posttrans-
plant months. The MMF has been associated with pneumonia due to pneumocystitis jirovecci, 
cytomegalovirus (CMV) disease, reactivation of Chagas disease, infection with Epstein-Barr 
virus (EBV), and risk of malignancy. On the other hand, patients with solid organ transplanta-
tion with hepatitis C seem to have better long-term outcomes with MMF therapy [88]. There 
is a strong association between the concentration of MPA, the pharmacological effects, and 
inter-individual variability between the MPA within the area under the curve (MPA AUC) 
estimated as the concentration of MMF after systemic elimination, enterohepatic recircula-
tion, and the concentration before the dose (C 0) [89].
Two analysis tools have been used for the measurement of MPA plasma levels: high performance 
liquid chromatography (HPLC) and enzyme multiplied immunoassay technique (EMIT). The 
EMIT is less specific in the measurement of MPA than HPLC: the concentrations of MPA that are 
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obtained by the EMIT method are typically higher than those of HPLC. The overestimation of 
the MPA concentration by the use of EMIT is approximately 24–35%. The degree of overestima-
tion varies depending on the patients’ characteristics, the time elapsed since the transplantation, 
and time of the blood sampling. However, in pediatric RT recipients the EMIT assay showed a 
diagnostic efficacy comparable to HPLC to assess the risk of AR, leaving EMIT as an acceptable 
monitoring tool for MPA. Therefore, either HPLC or EMIT can be used, although HPLC is a 
more specific analytical tool for the accurate assessment of MPA and metabolites [90, 91].
This clinical data supports the need for therapeutic monitoring of MPA. However, this could 
result in higher costs and time since the precise measurement of MPA AUC 0–12 h requires 
multiple blood samples during the dosing interval, which can be expensive and clinically 
impractical [91].
It is well established that in RT recipients, MMF reduces the risk of AR and improves graft 
survival; nonetheless, the side effects that include diarrhea in up to 37.3%, hematological 
alterations (leukopenia, anemia, thrombocytopenia), and an increase in the incidence of infec-
tions in 23–25% during the first year of transplantation, make it necessary to reduce the dose 
of MMF. Such side effects can be avoided by individualizing immunosuppression in patients, 
and other studies have demonstrated that the minimization strategies of immunosuppression 
must be adjusted according to the race, gender, and anthropometric characteristics at each 
transplant center [92].
8. New strategies for minimization of immunosuppressive therapy 
in kidney transplantation
8.1. Alemtuzumab
New strategies in the minimization of immunosuppression involve the use of alemtuzumab 
(humanized monoclonal antibody that targets CD52 on lymphocytes) used as a reduction 
strategy in doses of CNI and immunosuppression without steroids [93, 94].
Chan et al. [95], reported in 82 patients treated with alemtuzumab (TAC as monotherapy) 
versus 42 patients with daclizumab, TAC, and MMF; all with ESR, with results of a low AR 
incidence at 6 months posttransplant, and without differences in the survival of the graft or 
in its function, confirming the minimization of immunosuppression as a therapeutic strategy 
with this drug (Table 1).
In 3-year posttransplant follow-up studies, alemtuzumab combined with ESR has shown 
reduction in AR episodes in patients with low immunological risk compared to basiliximab-
based induction, while the presentation of AR was similar in those patients with high immu-
nological risk in whom immunosuppressive induction was compared with thymoglobulin. 
The main advantage of the use of alemtuzumab as a strategy to reduce immunosuppression 
is found in the availability to reduce the used dosage of CNI and the subsequent conversion to 
maintenance immunosuppression based on imTOR, whose main objective is to avoid chronic 
nephrotoxicity and improve graft survival and long-term function (Table 1) [96, 97].
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The therapeutic effect of alemtuzumab is not different from the immunological induction 
with thymoglobulin in the areas of AR incidence, delayed graft function, CMV infection, 
development of NODAT, and use of granulocyte colony stimulant [98].
8.2. Proteasome inhibitors
Proteasome nonselective inhibitors prevent the antibody-mediated AR of the graft. However, 
adverse effects outweigh the benefits by limiting their application in clinical practice. Up till 
now, the inhibition of immunoproteasomes is effective in experimental models in the context 
of autoimmune diseases being used for several weeks of treatment, without significant side 
effects. The ONX 0914, a selective proteasome inhibitor (B5i) of the LMP7 subunit, prevents 
chronic rejection in allogenic kidneys transplanted in rodents. The selective inhibition of immu-
noproteasomes by ONX 0914 and bortezomib reduces the number of plasma cells and B lym-
phocytes, and suppresses the formation of donor-specific antibodies in transplanted organs.
In renal grafts, T lymphocyte, B lymphocyte, and macrophage infiltration is reduced, as well 
as the complement deposit, interferon-γ, interleukin-17, and IgG [99].
Several series of cases have shown the efficacy of bortezomib in reversing the severe anti-
body-mediated rejection, establishing the maintenance therapy in posttransplant patients, 
and has even been used as a desensitization treatment in recipients with a positive cross test 
considered highly sensitized with satisfactory results; formulating guidelines to establish 
strategies for adjusting immunosuppression in long-term RT recipients. However, there are 
contradictory results. The BORTEJECT study [100] used bortezomib as a treatment for late 
antibody-mediated AR in 44 patients, with a follow- up of 3 years, with immunosuppres-
sion based on imTOR or CNI, with MMF 1–2 g/day and PDN, without finding a significant 
difference in the incidence of AR and renal function compared with placebo. Therefore, 
studies that evaluate the use of the drug in the induction and maintenance of immunosup-
pression are necessary to allow the minimization or optimization of the therapy used in 
selected cases (Table 1).
8.3. Belatacept
Belatacept (CTLA-4 Ig fusion protein) is a new drug with a mechanism of action that allows 
CNI-free maintained immunosuppression. Clinical studies show a higher incidence of T cell-
mediated AR in the first 6 months after transplantation, but show better long-term renal graft 
function. Likewise, the use of belatacept shows a lower incidence of DSA formation and less 
graft damage compared to the use of CsA. The most relevant adverse reactions include: her-
pes virus infections, tuberculosis, and a higher frequency of posttransplant lymphoprolifera-
tive disorders.
Belatacept has not yet been compared to a TAC/MMF-based regimen, considered the immu-
nosuppression maintenance standard in RT.
The current immunosuppressive treatment, far from being perfect, has contributed to the 
overall improvement of the renal graft and patient survival, which contributes to overcom-
ing the barrier for the development of new therapeutic agents. Consequently, most of the 
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new drugs have failed in the course of transplantation, including janus kinase inhibitors 
(tofacitinib), sphingosine-1-phosphate receptor modulator (FTY720, fingolimod), protein 
kinase C inhibitor (sotrastaurin, AEB), inhibitors of adhesion anti-LFA-1 molecules (efali-
zumab), anti-ICAM-1, and the first generation of anti-CD40-ligand. Most of the current 
treatments, still in research and focused on the immunology of the transplant, are biologi-
cal or cell-based treatments. The blocking of co-stimulation with the purpose to prevent T 
cell activation remains a point of interest. The ASKP1240, an anti-CD40 monoclonal anti-
body, has recently been tested in immunosuppression minimization regimens based on 
CNI dose reduction or suspension, compared to a control group based on standard dose 
TAC, finding higher AR and infection rates in the group treated with anti-CD40, so the 
future of this drug remains uncertain. More recently, CFZ533, a fully humanized mono-
clonal antibody has shown efficacy in primates, and clinical research is being initiated in 
humans (Table 1) [101].
8.4. Belimumab
Belimumab (human monoclonal antibody that inhibits B cell activating factor), approved for 
treatment in systemic lupus erythematosus (SLE), is in use in early-stage clinical studies for 
the prevention of antibody-mediated RA, as well as in patients sensitized with low titers of 
anti-donor-specific antibodies.
Cellular therapies represent an innovative therapeutic objective for the maintenance of long-
term renal graft, and thus avoidance of adverse reactions related to the maintenance of immu-
nosuppression. The premise of cell therapy is the induction of donor-specific nonresponse in 
the context of operational tolerance or mixed chimerism (Table 1) [100].
A single center study evaluated the autologous use of mesenchymal progenitor cells instead 
of the antibody-based induction with schemes based on low and high doses of CNI, compar-
ing induction with basiliximab and standard maintenance with MMF-CNI. The induction of 
autologous mesenchymal progenitor cells resulted in a lower AR rate, a decrease in opportu-
nistic infections, and better renal graft function 1 year after transplantation, concluding with 
conventional immunosuppressive maintenance [102].
Another study was carried out in hematopoietic progenitor cells transplant with HLA con-
cordant kidney donors in adjunct with total lymphoid radiation and thymoglobulin, which 
resulted in persistent mixed chimerism with stable renal graft function and removal of all 
immunosuppressants in 50% of the patients (Table 1) [103].
The most recently used strategies include the use of a product based on hematopoietic stem 
cells “facilitating cells” co-administered with nonmyeloablative reconditioning in living 
donor kidney graft recipients, reaching, in five out of eight patients, a satisfactory donor-
chimerism with successful immunosuppression maintenance withdrawal without evidence 
of AR or graft-versus-host disease [104].
The results of the previous studies, although very encouraging, should be validated in larger 
multi-centric controlled and randomized studies, from the safety-efficacy and cost–benefit 
points of view, compared with conventional immunosuppression therapy.
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